↓ Skip to main content

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016

Overview of attention for article published in Journal of Thoracic Oncology, May 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#4 of 3,511)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
65 news outlets
twitter
3 X users
patent
1 patent

Citations

dimensions_citation
177 Dimensions

Readers on

mendeley
171 Mendeley
Title
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
Published in
Journal of Thoracic Oncology, May 2016
DOI 10.1016/j.jtho.2016.05.008
Pubmed ID
Authors

Daniel S.W. Tan, Sue S. Yom, Ming S. Tsao, Harvey I. Pass, Karen Kelly, Nir Peled, Rex C. Yung, Ignacio I. Wistuba, Yasushi Yatabe, Michael Unger, Philip C. Mack, Murry W. Wynes, Tetsuya Mitsudomi, Walter Weder, David Yankelevitz, Roy S. Herbst, David R. Gandara, David P. Carbone, Paul A. Bunn, Tony S.K. Mok, Fred R. Hirsch

Abstract

Mutations in the epidermal growth factor receptor (EGFR) represent one of the most common "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKI) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of osimertinib, a 3(rd) generation EGFR TKI, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer (IASLC) commissioned consensus statement, key pathologic, diagnostic and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of re-biopsies and use of circulating free DNA (cfDNA) for molecular studies. With the rapid pace of progress in treating EGFR mutant NSCLC, this statement provides a state-of-the-art review of the contemporary issues in managing this unique subgroup of patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 171 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 2%
United Kingdom 1 <1%
Denmark 1 <1%
Unknown 166 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 30 18%
Other 21 12%
Student > Postgraduate 18 11%
Student > Ph. D. Student 16 9%
Student > Master 14 8%
Other 32 19%
Unknown 40 23%
Readers by discipline Count As %
Medicine and Dentistry 73 43%
Biochemistry, Genetics and Molecular Biology 24 14%
Agricultural and Biological Sciences 10 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 2%
Computer Science 3 2%
Other 11 6%
Unknown 46 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 512. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2020.
All research outputs
#49,607
of 25,371,288 outputs
Outputs from Journal of Thoracic Oncology
#4
of 3,511 outputs
Outputs of similar age
#1,004
of 348,582 outputs
Outputs of similar age from Journal of Thoracic Oncology
#1
of 53 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,511 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,582 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.